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Abstract
Background: Fifty random genetically unstudied families (limb-girdle muscular dystrophy (LGMD)/myopathy) were
screened with a gene panel incorporating 759 OMIM genes associated with neurological disorders. Average
coverage of the CDS and 10 bp flanking regions of genes was 99 %. All families were referred to the Neurosciences
Clinic of King Faisal Specialist Hospital and Research Centre, Saudi Arabia. Patients presented with muscle weakness
affecting the pelvic and shoulder girdle. Muscle biopsy in all cases showed dystrophic or myopathic changes. Our
main objective was to evaluate a neurological gene panel as a first-line diagnostic test for LGMD/myopathies.
Results: Our panel identified the mutation in 76 % of families (38/50; 11 novel). Thirty-four families had mutations
in LGMD-related genes with four others having variants not typically associated with LGMD. The majority of cases
had recessive inheritance with homoallelic pathogenic variants (97.4 %, 37/38), as expected considering the high
rate of consanguinity in the study population. In one case, we detected a heterozygous mutation in DNAJB
responsible for LGMD-1E. Our cohort included seven different subtypes of LGMD2. Mutations of DYSF were the
most commonly identified cause of disease followed by that in CAPN3 and FKRP. Non-LGMD myopathies were due
to mutations in genes associated with congenital disorder of glycosylation (ALG2), rigid spine muscular dystrophy 1
(SEPN1), inclusion body myopathy2/Nonaka myopathy (GNE), and neuropathy (WNK1). Whole exome sequencing
(WES) of patients who remained undiagnosed with the neurological panel did not improve our diagnostic yield.
Conclusions: Our neurological panel achieved a high clinical sensitivity (76 %) and is an effective first-line
laboratory test in patients with LGMD and other myopathies. This sensitive, cost-effective, and rapid assay
significantly assists clinical practice especially in these phenotypically and genetically heterogeneous disorders.
Moreover, the application of the American College of Medical Genetics (ACMG) and Association for Molecular
Pathology (AMP) guidelines applied in the classification of variant pathogenecity provides a clear interpretation for
physicians on the relevance of such findings.
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Background
The original definition of limb-girdle muscular dys-
trophy (LGMD) as non-Duchenne with autosomal reces-
sive inheritance was introduced in 1953 [1]. LGMD
classification has rapidly evolved since that time. A
major advance in neuromuscular disorders over the last
three decades has been the identification of many genes
underlying this group of heterogeneous diseases [2–4].
The LGMDs now vary widely in their genetics and also
in clinical features ranging from very mild forms which
allow patients to maintain a fairly normal life to much
more severe deterioration of proximal limb muscles that
causes dramatic physical weakness along with a short-
ened life-span [4, 5]. There are two major groups:
LGMD1 and LGMD2 with autosomal dominant and
autosomal recessive patterns of inheritance, respectively
[6]. To date, there are at least 8 genes associated with
LGMD1 (LGMD1A-1H) and 23 genes in which muta-
tions lead to different subtypes of LGMD2 (LGMD2A-
2W) [4] that continues to expand. This growing genetic
heterogeneity highlights the problem of a very complex
clinical diagnosis [7]. Current recommendations for
diagnosis and management of LGMD are very complex
and require access to multiple specialties including thor-
ough clinical examination, laboratory testing, muscle im-
aging, histological appearances of muscle, and more [5].
Since there are overlapping phenotypes in LGMDs and a
number of other myopathic disorders, a precise diagno-
sis without genetic testing is very difficult. As a conse-
quence of this, many patients remain undiagnosed.
Next-generation sequencing (NGS) also known as mas-
sively parallel sequencing has ushered in a new era in mo-
lecular diagnostics. The availability of exome sequencing
has been rapidly applied to clinical settings [8, 9]. Whiles
the cost of a clinical-grade whole exome sequencing
(WES) is still high and its interpretation very complex, an
alternative approach to WES is the use of a NGS-based
gene panel. This approach is particularly well suited for
genetically and clinically heterogeneous conditions where
the number and/or size of genes is too large and expensive
to sequence one gene at a time [10]. In this study, we
aimed to determine clinical sensitivity of a neurological
gene panel for diagnosis of LGMD/myopathies on the
basis that this would be a cheaper, more practical, and
effective approach.
Results
A total of 50 families were included in this study, of
which 36 had an autosomal recessive pattern of inherit-
ance with parental consanguinity. Mean age of disease
onset for our patients was 10.6 years. Distribution of
muscle weakness, age of onset, creatine kinase level, bi-
opsy findings, and other clinical characteristics are pre-
sented in the supplementary data (see Additional file 1).
Disease-causing mutations classified based on American
College of Medical Genetics (ACMG)/Association for
Molecular Pathology (AMP) guidelines were identified
in 76 % of the study cohort (38/50 families). Novel mu-
tations were present in 11 of these families (Table 1).
The neurological panel revealed pathogenic variants in
LGMD and non-LGMD myopathy related genes in 34
and 4 of our families, respectively (Table 2). The major-
ity of our cases with pathogenic causal variants were
homoallelic (97.4 %, 37/38), consistent with an auto-
somal recessive pattern of inheritance and as expected
within a highly consanguineous population [11, 12]. We
identified only one family with autosomal dominant
inheritance, the result of a heterozygous mutation in
DNAJB (LGMD type 1E), present in two affected meme-
bers (father and his son). The neurological panel
detected seven subtypes of LGMD2, mutations of DYSF
(LGMD2???) being the most common cause of the
disease. CAPN3 (LGMD2??) and FKRP(LGMD2??) were
two other commonly mutated genes in our study (Table 2).
Three affected members of family 25 had a homozy-
gous mutation in FKRP (c.C941T, p.T314M) that segre-
gated with disease with the exception of a 3-year-old
asymptomatic sister also homozygous for this allele. She
probably has not developed the phenotype yet as the
first symptoms associated with LGMD2I usually occur
between the first and third decade of life.
In several families, mutations in genes related to non-
LGMD myopathies were identified. Family 3 had a
mutation in ALG2 associated with a congenital disorder
of glycosylation. The patients presented with a congeni-
tal limb-girdle pattern of weakness with no ocular or
bulbar involvement. Muscle biopsies showed myopathic
features, ragged red fibers, and a sub-sarcolemmal accu-
mulation of structurally normal mitochondria. Family 16
had a mutation in SEPN1 associated with rigid spine
muscular dystrophy 1. The proband displayed major
weakness in lower extremities that progressed and
affected the upper proximal shoulder and girdle muscles.
He suffered from respiratory failure and kyphoscoliosis.
Needle EMG examination and nerve conduction studies
were consistent with myopathy.
The index patient from family 24 presented with prox-
imal muscle weakness of the lower extremities that
started after the delivery of her first child. The condition
progressed in severity and she started to note frequent
falls and tripping after delivery of her second child.
Nerve conduction studies as well as the needle EMG
were consistent with a clinical diagnosis of progressive
distal myopathy. In this patient, a mutation in GNE
(UDP-N-acetyloglucosamine 2-epimerase/N-acetylman-
nosamine kinase) associated with inclusion body
myopathy2/Nonaka myopathy was identified. Neuropathy
due to mutation in WNK1 was found to underlie disease
Monies et al. Human Genomics  (2016) 10:32 Page 2 of 7
in family 26. The female patient was normal until the age
of 9, when she had a problem with standing and walking.
She developed full Gower’s sign and had frequent falls.
The girl had a global proximal weakness affecting, lower
more than the upper, extremities. There was also bilateral
mild hypertrophy of the calf muscles with a marked lordo-
tic gait. Muscle biopsy showed clear dystrophic changes.
She had a similarly affected sister.
We performed WES on nine neurological panel “nega-
tive” consanguineous multiplex families with autosomal
recessive disease inheritance. Accordingly, we concen-
trated on finding pathogenic homozygous variants
within defined ROHs (shared by affected individuals
only). WES did not reveal any such variants, in particu-
lar among neuromuscular genes within these regions.
Discussion
High-throughput solutions such as NGS have revolu-
tionized the genetic approach for molecular diagnosis of
Mendelian disorders. Utility of WES in the clinic has
Table 1 Summary of findings in positive cases and mutation classification based on ACMG/AMP guidelines
Index ID Gene Mutation Novel Effect Evidence of pathogenicity
10R-00963
10R-00534





FKRP NM_001039885:c.941C>T;p.T314M No Pathogenic PP1-S, PM2, PM3, PP1-M, PP1, PP3, PP2, PP4
11R-00685 ALG2 NM_033087.3:indel:c.214_224delGGGGACTGGCT
delinsAGTCCCCG;p.72_75delGDWLinsSPR







DYSF NM_003494:c.164_165insA;p.I57Hfs*8 No Pathogenic PVS1, PP1-S, PM2, PM3, PM4, PP1-M, PP1, PP3, PP4
11R-00680
10R-00857




SGCA NM_001135697:c.101G>A;p.R34H No Pathogenic PM2, PP1-S, PM3, PP1-M, PP1, PP2, PP3, PP4
10R-00739 CAPN3 NM_000070:cA2329A>G;p.I777V Yes Pathogenic PP1-S, PM2, PM3, PP1-M, PP1, PP2, PP3, PP4
10R-00751 SEPN1 NM_206926:c.1270G>A;p.D424N Yes Pathogenic PP1-S, PM2, PM3, PP1-M, PP1, PP2, PP3, PP4
10R-00779 CAPN3 NM_000070:c.146G>A;p.R49H No Pathogenic PP1-S, PM2, PM3, PP1-M, PP1, PP2, PP3, PP4
10R-00926 SGCB NM_000232:c.355A>T;p.I119F No Pathogenic PP1-S, PM2, PM3, PP1-M, PP1, PP2, PP3, PP4
10R-00973 FKTN NM_006731:c.314G>T;p.C105F No Pathogenic PP1-S, PM2, PM3, PP1-M, PP1, PP2, PP3, PP4
11R-00018
13R-01080
CAPN3 NM_000070:c.1699G>A;p.G567R Yes Likely pathogenic PM2, PM3, PP2, PP3, PP4
11R-00031 GNE NM_001190384:c.1805T>C;p.M602T No Pathogenic PP1-S, PM2, PM3, PP1-M, PP1, PP2, PP3, PP4
11R-00230
12R-01188
FKRP NM_001039885:c.941C>T;p.T314M No Pathogenic PP1-S, PM2, PM3, PP1-M, PP1, PP2, PP3, PP4
11R-00232 WNK1 NM_213655:c.2152C>T:p.R718C Yes Pathogenic PP1-S, PM2, PM3, PP1-M, PP1, PP2, PP3, PP4
11R-00308
12R-01189
DYSF NM_001130976:c.1433delC;p.T478fs Yes Pathogenic PVS1, PP1-S, PM2, PM3, PM4, PP1-M, PP1, PP4, PP3
11R-00337 FKRP NM_001039885:c.1012G>T;p.V338L Yes Pathogenic PP1-S, PM2, PM3, PP1-M, PP1, PP2, PP3, PP4
11R-00745 DYSF NM_001130976:c.A5201T;p.E1734V No Pathogenic PP1-S, PM2, PM3, PP1-M, PP1, PP2, PP3, PP4
11R-02618 CAPN3 NM_000070:c.310G>T;p.E104X Yes Pathogenic PVS1, PM2, PM3, PM4, PP3, PP4
12R-00001 ANO5 NM_001142649, c.169C>T;p.R57W No Pathogenic PP1-S, PM2, PM3, PP1-M, PP1, PP2, PP3, PP4
12R-00316 CAPN3 NM_000070:c.2381-1G>A Yes Pathogenic PVS1, PM2, PM3, PM4, PP1-M, PP1-S, PP1, PP3, PP4
13R-01177 DYSF NM_001130976:c.89-1G>A Yes Pathogenic PVS1, PP1-S, PM2, PM3, PM4, PP1-M, PP1, PP3, PP4
14R-00183 DNAJB6 NM_005494:c.C287T;p.P96L Yes Pathogenic PP1-S, PM2, PP1-M, PP1, PP2, PP3, PP4
ACMG/AMP American College of Medical Genetics and Genomics/Association for Molecular Pathology, PVS1 pathogenic very strong, PM2-4 pathogenic moderate,
PP1-4 pathogenic supporting, PP1-M pathogenic supporting (moderate), PP1-S pathogenic supporting (strong)
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been relatively successful, mainly for neurological condi-
tions, with a yield of ~25 % [9, 13]. Due to high cost, a
long turnaround time and challenging interpretation,
arguably, WES should be considered mainly for the pur-
pose of novel gene discovery. An alternative solution
that substantially reduces the above limitations is an
approach which targets known disease genes grouped in
panels [14]. Several approaches have been taken to
design and sequence NGS-based gene panels for LGMD
patients [7, 15–19]. In our study, the neurological gene
panel comprised 759 genes known to cause Mendelian
neurological diseases (not only LGMD) as annotated by
OMIM up to August 2013. The neurological panel is a
part of our Mendeliome assay that includes 13 symp-
tom/sign-based gene panels [14]. Minimal expertise is
required by clinicians to choose the neurological panel
from the 13 present in the “Mendeliome,” e.g., any
muscle weakness or movement problem will trigger test-
ing for this panel. This comprehensive assay simplifies
the molecular diagnostic process and takes into consid-
eration the remarkable phenotypic variability between
many neuromuscular disorders. In this way, we signifi-
cantly reduce the chance of missing a genetic diagnosis
due to atypical presentation.
In our cohort of 50 LGMD families, the neurological
panel was able to resolve 76 % of cases (38/50 families),
an exceptionally high diagnostic yield relative to previ-
ously published data (Table 3). In light of ambiguity
associated with clinical significance of NGS variants,
assigning an objective assessment of pathogenicity is
crucial in making a molecular diagnosis. We interpreted
the clinical significance of our findings (those which
survived our filtration process) using ACMG/AMP
standards and guidelines. This objective and standard-
ized approach to variant classification, while clearly indi-
cated in clinical situations, has not been applied by
previous studies evaluating NGS for diagnosis of myop-
athies [7, 15–21]. Given the nature and number of
variants identified using NGS, we feel that classification
in this manner is not only useful but also essential to
clear interpretation by referring physicians. All but one
disease associated variant identified in our cohort were
classified as pathogenic. The one exception was classified
as a likely pathogenic, consequent to there being only
one affected member in the family, thus preventing
demonstration of co-segregation with multiple affected
individuals (Table 1).
The panel covers all types of muscular dystrophies, my-
opathies, and other neuromuscular disorders encompass-
ing more than 300 diseases to date [22]. Unfortunately,
most of them have very similar clinical presentations and
even with thorough clinical evaluation and muscle path-
ology, a correct diagnosis without genetic testing remains
difficult. A strong case may be made to test all muscle
genes in analysis of patients with suspected LGMD [20].
In similar studies, a diagnostic yield of LGMD
patients using a gene panel approach varies from 16
to 65 % [7, 20]. In these studies, the number and
composition of genes sequenced were associated with
diagnostic yield. Ankala and colleagues, by expanding
their LGMD panel with 11 genes to a more compre-
hensive neuromuscular disease (NMD) panel contain-
ing 41 genes, achieved a threefold greater diagnostic
rate. Their NMD panel also covered other
non-LGMD movement disorders and increased the
yield from approximately 15 to 46 % [18]. Dai et al.
claimed to have designed a panel of 44 known genes
underlying muscular dystrophies and congenital
myopathies. In fact, their libraries incorporated 399
genes covering common inherited disorders including
at least 55 genes associated with myopathies. They
were able to find causative mutations in 65 % of
Table 2 Overview of the genetic diagnosis based on the
neurological panel results
Genetic diagnosis Number of
families (n = 50)
Inheritance
Dyspherlinopathy 10 (20 %) AR
Calpainopathy 8 (16 %) AR
Dystroglycenopathy (type C) 7 (14 %) AR
α-Sarcoglyconapthy 5 (10 %) AR
β-Sarcoglyconapthy 1 (2 %) AR
Dystroglycenopathy (type B) 1 (2 %) AR
Anoctaminopathy 1 (2 %) AR
Congenital disorder of glycosylation 1 (2 %) AR
Rigid spine muscular dystrophy 1 (2 %) AR
Nonaka myopathy 1 (2 %) AR
Neuropathy 1 (2 %) AR
Limb-girdle muscular dystrophy, type 1E 1 (2 %) AD
Undiagnosed 12 (24 %)
AR autosomal recessive, AD autosomal dominant
Table 3 Diagnostic yield of gene panels in LGMD/myopathic
patients










Ghosh at al. [15] 9 27 10 (37 %)
Savarese et al. [7] 93 177 108 (61 %)
Seong et al. [17] 18 35 20 (57 %)
Ankala et al. [18] 11 96 25 (26 %)
Dai et al. [19] 399 55 36 (65 %)
Kuhn et al. [20] 38 58 19 (33 %)
Our study 759 50 38 (76 %)
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patients [19]. The MotorPlex assay comprising 93
muscle disease loci identified pathogenic or potential
causative variants in 61 % of patients tested [7]. Bet-
ter performance of our panel (diagnostic yield = 76 %)
versus others described may be associated with it be-
ing more comprehensive (759 genes) and its applica-
tion in an inbred population. Our neurological panel
was able to diagnose patients due to mutations in
genes absent in assays described in other studies.
Those gene panels would miss at least 8 to 10 % of patho-
genic changes in our cohort. The Athena Diagnostics
LGMD gene panel would not detect a mutation in seven
of our cases: FKTN, ANO5, DNAJB6, SEPN1, GNE,
WNK1, and ALG2 [15]. Both assays used by Ankala et al.
and Seong et al. would miss diagnosis due to changes in
four to five genes (DNAJB6, GNE, WNK1, ALG2, and
SEPN1) [17, 18]. Two other panels would fail to diagnose
patients from our cohort with disorders associated with
DNAJB6, WNK1, and ALG2 [19] and SEPN1, WNK1, and
ALG2 [20]. While our neurological panel could be focused
further, there is little to be gained from doing so other
than to perhaps reduce incidental findings. Ghaoui and
colleagues tested 60 LGMD families (undiagnosed by con-
ventional candidate gene sequencing) using WES with a
diagnostic success rate of 45 %. The identified mutations
were present only in known myopathy genes and WES
did not reveal any finding in novel genes. The group ob-
tained identical results by retesting the samples using a
neuromuscular panel which contained 336 neuromuscular
disease-related genes. The panel confirmed all variants
identified by WES highlighting the benefit of a panel-
based approach relative to candidate gene sequencing or
WES [21]. Comprehensive gene panels should be viewed
as first-tier tests before considering WES. Based on our
results and reports in the literature cited above, we con-
sider application of gene panels to be a more effective
approach for diagnosis of myopathies.
Considering very high genetic heterogeneity (similar
phenotype associated with multiple genes) and phenotypic
heterogeneity (a single gene associated with multiple phe-
notypes) in LGMD and other myopathies, applying a gene
panel (such as our neurological panel), incorporating a
comprehensive list of genes associated with neuromuscular
disorders, that can be tested together at the same time, pro-
vides a very powerful and practical diagnostic tool. Besides
the high diagnostic efficiency, our neurological panel is
cost-effective. A multiplexing strategy running 24 samples
per run dramatically reduces the sample processing cost
(~$150) and time. A similar approach was taken by
Savarese and colleagues who designed the MotorPlex panel
(93 genes) covering all known forms of non-syndromic
muscle disorders. They also applied a cost-effective pooled
sequencing strategy with 100 % specificity and sensitivity of
the assay in 20 LGMD or congenital myopathy patients [7].
Molecular diagnosis is crucial for genetic counseling
and prognosis [23, 24]. An earlier genetic diagnosis pro-
vides better disease management and also protects
patients from more invasive clinical evaluation [25].
WES applied to the remaining undiagnosed multi-
plex families (n = 9) did not detect any disease-
causing mutations. The use of NGS technology, as
applied in this study, has limitations including incom-
plete coverage of target sequences in PCR based
libraries, amplification bias resulting non-uniform
coverage of library amplicons, inability to detect
structural changes, and poor sensitivity for copy num-
ber variation. We cannot exclude possibility of
missing mutations in known genes which are not fully
covered or those present in intronic regions which
are not covered by WES [26, 27]. Another NGS limi-
tation is copy number variation (CNV) (gross
deletions and insertions) which are poorly detected so
far by this approach [20]. WES results of our and other
studies [21] also suggest that the majority of genes under-
lying LGMD and other myopathies have probably been
identified with limited scope for novel discovery.
Conclusions
We have demonstrated that our neurological panel assay
covering 759 neurological genes cited by OMIM has a
high diagnostic yield (76 %) for LGMD and other myop-
athies. In addition, it is a rapid and cost-effective assay.
We believe that the majority of LGMD patients can be
diagnosed using this new very powerful genomic tool
and WES should be reserved only for negative cases as
an opportunity to discover novel candidate genes. Classi-
fication of disease-associated variants with respect to
pathogenicity, using guidelines of the ACMG/AMP as
applied in our study further, adds to the power and util-




A total of 50 random genetically unstudied families were
included in this study; 36 and 14 of these were multiplex
and simplex families, respectively. All were collected
through neurosciences clinic at KFSHRC between 2010
and 2015. The age of disease onset varied from 1 to
35 years. All patients presented with muscle weakness
affecting the pelvic and shoulder girdle. Muscle biopsy in
all individuals showed dystrophic or myopathic changes.
DNA was extracted from peripheral blood samples
using standard procedures (Flexi Gene DNA Handbook,
Qiagen). Samples were quantitated spectrophotometrically
and stored at −20 °C.
Monies et al. Human Genomics  (2016) 10:32 Page 5 of 7
Neurological panel assay and bioinformatics analysis
This gene panel was a part of the NGS targeted rese-
quencing “Mendeliome” assay that consists of 13
symptom-based gene panels which cover all inherited
disease associated genes in OMIM as of August 2013
[14]. The neurological panel included 759 OMIM genes
associated with neurological disorders (see Additional
file 2). Genes were amplified and a library constructed
using an AmpliSeq HiFi mix, proprietary primers (see
Additional file 3) and library kit (Thermo Fisher,
Carlsband, CA, USA) followed by sequencing on the Ion
Proton platform according to the manufacturer’s proto-
col (Thermo Fisher, Carlsband, CA, USA). Variants were
called and annotated using the Saudi Human Genome
pipeline [14]. Briefly, only regions of the reads with high
quality (Ion Torrent base calling algorithm, Thermo
Fisher, Carlsband, CA, USA) were aligned to the UCSC
hg19 (http://genome.ucsc.edu/) reference sequence and
processed for variant calling using the Torrent Suite
Variant Caller (TVC) program (Thermo Fisher, Carlsband,
CA, USA). Performance of the neurological panel in this
study resulted in >95 % of reads at Q17 with an average
read depth of 166 X. Variants were annotated using in-
house programs that extend the public Annovar pack-
age with other licensed commercial data sets such as
the professional version of HGMD [28] and in-house
databases made up of a collection of disease-causing
and polymorphic variants observed in individuals of
Arab ethnicity. As a final step, non-relevant variants
were filtered out based on their quality, functional char-
acteristics, and their frequency in our datasets. Intronic
variants, synonymous variants, and those present in
population databases (specifically those that are in 1000
Genome database with MAF >1 %) were also filtered out.
Furthermore, variants that were frequent (MAF >1 %) in
our population specific in-house variant database were
also filtered out. After applying filtration criteria, all non-
sense, frameshift, and canonical splice site variants were
considered pathogenic. For interpretation and classifica-
tion of the remaining SNVs, nucleotide and amino acid
conservation and effects on protein sequence were ana-
lyzed with PolyPhen-2 (http://genetics.bwh.harvard.edu/
pph2/) and SIFT (http://sift.jcvi.org/). Potential causative
variants were validated by Sanger sequencing and further
vetted for familial segregation. Finally, the remaining vari-
ants were identified as pathogenic or likely pathogenic
following guidelines of the American College of Medical
Genetics (ACMG) and Association for Molecular Path-
ology (AMP) [29].
DNA Sanger sequencing
Coding regions of candidate genes were sequenced using
a BigDye Terminator kit (Applied Biosystems, Foster
City, CA) and run on an ABI 3730xl automated
sequencer (Applied Biosystems, Foster City, CA).
SeqScape v.2.6 software (Applied Biosystems, Foster
City, CA) was used to align sequence data against the
relevant reference.
Genetic variant interpretation, ACMG/AMP guidelines
The clinical significance of NGS variants was classified
using an openly available online tool for implementing
the ACMG/AMP standards and guidelines: http://
medschool.umaryland.edu/Genetic_Variant_Interpretation_
Tool1.html. [30].
Genotyping and homozygosity mapping
All participating individuals (affected and unaffected) in
cases where the neurological panel failed to identify a likely
casual mutation were genotyped using the Affymetrix
Axiom array (Affymetrix, Santa Clara, CA, USA) following
the manufacturer’s protocol (http://www.affymetrix.com/
support/technical/manuals.affx). Resulting genotypes were
analyzed for shared runs of homozygosity (ROH) using
autoSNPa (http://dna.leeds.ac.uk/autosnpa/).
Whole exome sequencing and analysis
Multiplex families that tested negative on the neuro-
logical panel underwent WES. Briefly, 100 ng of each
DNA was amplified in 12 separate wells using Exome
Primer Pools, AmpliSeq HiFi mix (Thermo Fisher,
Carlsbad, CA, USA) and 10 amplification cycles. All 12
PCR pools were combined in one well and subjected to
primer digestion by incubation with FuPa reagent
(Thermo Fisher, Carlsbad, CA, USA). Amplified Exome
targets were ligated with Ion P1 and Ion Xpress Barcode
adapters. After purification, libraries were quantified
using qPCR with the Ion Library Quantification Kit
(Thermo Fisher, Carlsbad, CA, USA). The prepared
exome library was further used for emulsion PCR on
an Ion OneTouch System and templated Ion Sphere
particles were enriched using Ion OneTouch ES, both
procedures following the manufacturer’s instructions
(Thermo Fisher, Carlsbad, CA, USA). The template-
positive Ion PI Ion Sphere particles were processed
for sequencing on the Ion Proton instrument
(Thermo Fisher, Carlsbad, CA, USA). Reads were
mapped to UCSC hg19 (http://genome.ucsc.edu/) and
variants identified using the Saudi Human Genome
Program (SHGP) pipeline [14].
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